How does injectable stanozolol fit into a modern periodised anabolic cycle?

Injectable stanozolol functions best as a phase-specific compound rather than a full-cycle base. In modern periodised programming it is introduced during the transition or finishing phase — typically the final six to eight weeks — where its rapid SHBG suppression and lean-tissue preservation effects are most productive. It complements longer-acting base compounds already at steady state rather than serving as the primary anabolic driver.

At what point in a cycle should you start Nassa Labs Stanozolol Injection 50mg/ml?

Most modern protocols introduce it four to eight weeks before the cycle endpoint, once the base compound has reached stable plasma concentrations. Starting it too early wastes the compound's peak effect on a phase where its specific strengths — hardening, strength retention, SHBG reduction — are less relevant. Beginning at the transition into the finishing window maximises its contribution to the cycle's final objectives.

How long should a stanozolol injection cycle run for optimal results and manageable risk?

Contemporary evidence-informed guidelines cap stanozolol inclusion at six to eight weeks within the broader cycle. Beyond eight weeks, cumulative HDL suppression and joint-dryness side effects become increasingly difficult to manage without compromising overall health markers. Running it within this window, monitored by lipid panels at baseline and week four, balances efficacy against a manageable side-effect profile as documented in clinical lipid-monitoring datasets.

Why is the 50mg/ml concentration considered easier to work with for insulin-syringe dosing?

At 50mg/ml, a 25mg dose requires exactly 0.5ml and a 50mg dose requires exactly 1.0ml — volumes that correspond directly to standard insulin-syringe graduation marks without requiring fractional calculations. This makes the concentration the most error-resistant option in the injectable stanozolol range for practitioners who prefer insulin syringes for subcutaneous or shallow intramuscular administration, where measurement precision matters most.

How should a 10ml vial of Nassa Labs Stanozolol Injection be stored after opening?

After first puncture, the vial should be stored upright in a refrigerator at 2–8°C and used within 28 days. Aqueous suspensions are more susceptible to microbial contamination after the stopper seal is breached than oil-based formulations; consistent cold storage slows any bacterial proliferation. Inspect the suspension visually before each draw — discard if the liquid appears cloudy, discoloured, or contains particulate matter not resolved by gentle agitation. (2) angle_used

Advanced Formula

Nassa Labs

Stanozolol injectable 50mg/ml 10ml Vial by Nassa Labs

Name: Stanozolol injectable 50mg/ml 10ml Vial by Nassa Labs
Brand: Nassa Labs
SKU: INJ-STAN-NAS-50-013
Price: 36.00 EUR
Availability: InStock

Nassa Labs Stanozolol Injection delivers 50mg of stanozolol per millilitre in an aqueous injectable format, purpose-built for integration into structured modern anabolic cycles where phase timing and compound sequencing determine outcomes. At 50mg/ml, the concentration gives cycle designers clean, predictable volume increments across preparation, contest, and recomposition phases — a practical advantage when adjusting dose without reformulating the protocol. Quality assurance is enforced at batch level: HPLC content verification and LAL endotoxin screening are completed on each specific production lot, with results archived against the vial's unique batch code.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Phase-specific placement in finishing or transition blocks of a structured cycle maximises compound efficiency
Rapid plasma clearance (~24 hours) allows precise cycle endpoint control without extended washout delays
50mg/ml concentration maps directly to 0.5ml and 1.0ml syringe markings for volumetric precision
SHBG suppression documented at clinically meaningful levels within two weeks, amplifying free androgen activity from co-administered compounds
Lot-specific HPLC content assay and LAL endotoxin certification on every 10ml batch — not extrapolated from adjacent production runs
10ml multi-dose vial format provides sufficient volume to complete a full six-to-eight-week cycle window from a single unit
Short-acting aqueous profile allows mid-protocol dose adjustments to take effect within days rather than weeks

Phase	dosage	Note
Cycle Entry / Transition (Weeks 1–2)	25mg every other day (0.5ml per injection)	Introductory dose to assess tolerability; SHBG suppression begins within the first week. Lipid baseline panel recommended before first injection.
Mid-Phase Build (Weeks 3–5)	50mg every other day (1.0ml per injection)	Full cycle dose aligned with the finishing phase window. Monitor HDL at week 4; adjust down to 25mg EOD if lipid values decline beyond acceptable range.
Peak / Pre-Endpoint (Weeks 6–8)	50mg daily or 50mg every other day (maintained)	Daily frequency reserved for experienced users approaching a competitive or physique endpoint. Hard cap at 8 weeks total inclusion; do not extend beyond this window.
Cycle Exit	Discontinue fully — no taper required	Rapid plasma clearance means discontinuation is clean. Begin PCT planning relative to the last injection of any long-ester base compound still active in the cycle.

Key takeaways

Position stanozolol injection in the finishing phase of your structured cycle.
Limit cycle inclusion to six to eight weeks for manageable lipid impact.
Use 50mg/ml concentration for clean, syringe-readable dose increments.
Monitor HDL cholesterol with a lipid panel at baseline and week four.
Verify batch authenticity via Nassa Labs' HPLC and LAL certificate records.

What Nassa Labs Stanozolol Injection Brings to a Structured Cycle

Nassa Labs Stanozolol Injection 50mg/ml is an aqueous injectable anabolic agent whose primary role in contemporary programming is as a phase-specific tool rather than a standalone compound — placed deliberately within a cycle to fulfil defined objectives at defined windows. This distinguishes it from compounds used at flat-dose throughout: stanozolol's short plasma residence time (approximately 24 hours in aqueous suspension, established by radioimmunoassay profiling) makes it a compound that responds quickly to dose adjustments, which is exactly what modern periodised cycle design demands.

Phase Placement in Modern Cycle Architecture

Modern cycle planning organises compounds by phase function: base-building, strength transition, and finishing. Stanozolol occupies the transition and finishing phases with particular efficiency. Compared to long-ester androgens deployed in the base phase, injectable stanozolol clears rapidly on cessation, giving cycle architects precise control over the compound's presence as stage day or a testing window approaches. The 50mg/ml concentration accommodates the 25–50mg every-other-day dosing range most frequently documented in contemporary performance literature without requiring sub-0.5ml measurements that introduce volumetric imprecision.

Cycle-Length Considerations

Evidence-informed modern protocols typically cap injectable stanozolol inclusion at six to eight weeks within a longer cycle. This ceiling exists because SHBG suppression and HDL cholesterol reduction accumulate over time; restricting the compound to a defined window manages cumulative cardiovascular and hepatic load while preserving the anabolic stimulus during the period it is most needed. A lipid panel at cycle entry and at the four-week mark provides the monitoring data needed to make mid-cycle adjustments.

Nassa Labs Formulation Standards

Nassa Labs subjects each 10ml batch of Stanozolol Injection to lot-specific HPLC content assay, confirming API concentration against validated in-house acceptance criteria — not extrapolated from a prior run. The LAL (Limulus Amebocyte Lysate) endotoxin test is applied batch-specifically to every aqueous injectable lot, as the water-based vehicle presents a contamination risk profile absent from oil-based formulations. Each vial carries a batch code linked to these certificates in Nassa Labs' traceability register.

Usage

Plan the placement before cycle start.: Confirm the cycle's total duration and identify the final six to eight weeks as the stanozolol window; document which base compound(s) are concurrently active and their respective ester clearance timelines.
Inspect and prepare the vial.: Check the batch code against Nassa Labs' certificate records. Invert gently to resuspend the aqueous particles, then check that the suspension is uniform and free from abnormal discolouration before drawing.
Draw the dose using a clean technique.: Wipe the rubber stopper with an alcohol swab and allow it to dry fully. Use a fresh 21–23G draw needle to fill the syringe, then switch to a 25G injection needle to minimise injection-site trauma.
Select and rotate injection sites.: Gluteus, vastus lateralis, and deltoidal sites are suitable; rotating across sites each injection reduces localised tissue irritation from the aqueous vehicle.
Administer and record.: Inject slowly and steadily. Log the date, dose volume, and injection site in a cycle diary — this supports the mid-cycle lipid review and documents the compound's exact position within the broader protocol timeline.
Store the vial correctly between uses.: Return the punctured vial to refrigerated storage (2–8°C), upright, and away from light. Use within 28 days of first opening; discard if suspension integrity changes.

Warnings

contraindications: Not for use in individuals with active hepatic disease, elevated liver enzymes at baseline, or existing cardiovascular disease. Contraindicated in women who are pregnant or may become pregnant. Individuals with a personal or family history of prostate carcinoma should not use this product.

side_effects: Androgenic effects include accelerated androgenic alopecia in predisposed individuals and potential voice-pitch changes in female users. Cardiovascular: HDL reduction accumulates over the course of administration and is dose-duration dependent — monitored by lipid panel. Joint discomfort attributable to reduced synovial fluid is reported by a subset of users during high-volume training phases. Hepatotoxicity is lower with the injectable route than with the 17-alpha-alkylated oral form, but elevated liver enzymes remain possible.

monitoring: Baseline lipid panel before cycle start; repeat at the four-week mark of stanozolol administration. Liver function tests (ALT, AST) at baseline and mid-cycle. Blood pressure checks at least fortnightly. Female users: monitor for early virilisation signs and discontinue immediately if irreversible androgenic changes appear.

pct: Post-cycle therapy timing is governed by the longest-ester compound in the cycle, not by stanozolol's own clearance. Because stanozolol clears within approximately 24–48 hours, PCT initiation should be timed to the ester with the longest residual plasma presence. Standard SERM-based PCT (tamoxifen or clomiphene) applies for cycles including testosterone or other suppressive androgens.

Frequently asked questions

How does injectable stanozolol fit into a modern periodised anabolic cycle?: Injectable stanozolol functions best as a phase-specific compound rather than a full-cycle base. In modern periodised programming it is introduced during the transition or finishing phase — typically the final six to eight weeks — where its rapid SHBG suppression and lean-tissue preservation effects are most productive. It complements longer-acting base compounds already at steady state rather than serving as the primary anabolic driver.
At what point in a cycle should you start Nassa Labs Stanozolol Injection 50mg/ml?: Most modern protocols introduce it four to eight weeks before the cycle endpoint, once the base compound has reached stable plasma concentrations. Starting it too early wastes the compound's peak effect on a phase where its specific strengths — hardening, strength retention, SHBG reduction — are less relevant. Beginning at the transition into the finishing window maximises its contribution to the cycle's final objectives.
How long should a stanozolol injection cycle run for optimal results and manageable risk?: Contemporary evidence-informed guidelines cap stanozolol inclusion at six to eight weeks within the broader cycle. Beyond eight weeks, cumulative HDL suppression and joint-dryness side effects become increasingly difficult to manage without compromising overall health markers. Running it within this window, monitored by lipid panels at baseline and week four, balances efficacy against a manageable side-effect profile as documented in clinical lipid-monitoring datasets.
Why is the 50mg/ml concentration considered easier to work with for insulin-syringe dosing?: At 50mg/ml, a 25mg dose requires exactly 0.5ml and a 50mg dose requires exactly 1.0ml — volumes that correspond directly to standard insulin-syringe graduation marks without requiring fractional calculations. This makes the concentration the most error-resistant option in the injectable stanozolol range for practitioners who prefer insulin syringes for subcutaneous or shallow intramuscular administration, where measurement precision matters most.
How should a 10ml vial of Nassa Labs Stanozolol Injection be stored after opening?: After first puncture, the vial should be stored upright in a refrigerator at 2–8°C and used within 28 days. Aqueous suspensions are more susceptible to microbial contamination after the stopper seal is breached than oil-based formulations; consistent cold storage slows any bacterial proliferation. Inspect the suspension visually before each draw — discard if the liquid appears cloudy, discoloured, or contains particulate matter not resolved by gentle agitation. (2) angle_used

Manufacturer

Nassa Labs' development work on its injectable stanozolol formulation centred on a challenge that is particular to aqueous suspensions: ensuring that API particle distribution remains consistent across the full volume of a 10ml multi-dose vial through repeated puncture and storage cycles. Rather than relying on a generic suspension excipient template, Nassa Labs validated the stanozolol 50mg/ml formulation through a purpose-built resuspension characterisation protocol — confirming that the declared concentration is recoverable from the first draw and the final draw from the same vial, not just from the mid-fill zone. This formulation-specific validation is part of the development record for the stanozolol product line and distinguishes it from Nassa Labs' oil-based injectables, which do not face the same homogeneity challenge. Batch release incorporates HPLC content assay and LAL endotoxin testing on the actual production lot; results are archived against the specific batch code printed on each vial, not averaged across a campaign.

Product details

Brand	Nassa Labs
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Stanozolol injectable, Nassa Labs Winstrol Depot
Strength	50 mg
Form	Vial
Pack size	1 piece
Item number	INJ-STAN-NAS-50-013

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00